A Retrospective Study of Dexamethasone, Remdesivir, and Baricitinib in Severe COVID-19

Table 1

Baseline demographic and clinical characteristics.

	Baricitinib + dexamethasone + remdesivir n = 81	Dexamethasone + remdesivir n = 110	Odds ratio	value	95% CI
BMI			1.01	0.55	0.97–1.05
Mean	31.87 ± 0.78	30.36 ± 0.90
Median	31.7	29.75
Age			0.99	0.38	0.97–1.01
Mean	61.67 ± 1.76	64.68 ± 1.67
Median	62	63
Gender (%)			0.56	0.07	0.29–1.05
Male	50 (61.73)	82 (74.55)
Female	31 (38.27)	28 (25.45)
Race (%)			0.95	0.37	0.86–1.05
American Indian or Alaskan native	1 (1.23)	1 (0.91)
Asian	3 (3.7)	1 (0.91)
Asian Indian	7 (8.64)	5 (4.55)
Black	14 (17.28)	23 (20.91)
Filipino	2 (2.47)	3 (2.73)
Samoan	0 (0)	2 (1.82)
Other Pacific islander	2 (2.47)	1 (0.91)
White	40 (49.38)	63 (57.27)
Unknown	2 (2.47)	0 (0)
Patient declined	10 (12.35)	11 (10)
Ordinal score (%)
4 = hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise	3 (3.7)	10 (9.09)
5 = hospitalized, requiring supplemental oxygen	25 (30.86)	48 (43.64)
6 = hospitalized, on noninvasive ventilation or high-flow oxygen devices	53 (65.43)	52 (47.27)
Pre-existing comorbidities (%)
Asthma	6 (7.41)	6 (5.45)	1.52	0.5	0.45–5.10
Congestive heart failure	7 (8.64)	14 (12.73)	0.86	0.79	0.29–2.53
Chronic kidney disease	9 (11.11)	24 (21.81)	0.46	0.1	0.18–1.16
Chronic obstructive pulmonary disease	7 (8.64)	9 (8.18)	1.2	0.74	0.41–3.53
Diabetes	36 (44.44)	42 (38.18)	1.53	0.19	0.81–2.87
Hyperlipidemia	41 (50.61)	47 (42.73)	1.62	0.16	0.83–3.16
Hypertension	44 (54.32)	68 (61.82)	0.63	0.19	0.32–1.25
Hypothyroidism	11 (13.58)	11 (10)	1.62	0.31	0.64–4.11
Tocilizumab (%)	17 (20.99)	28 (25.45)	0.93	0.86	0.43–2.03